Lunac Therapeutics Ltd. has synthesized coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of arthritis, Alzheimer's disease, disseminated intravascular coagulation, pulmonary embolism, myocardial infarction, diabetic retinopathy, stroke and deep venous thrombosis, among others.

Nanjing Kangyi Biomedical Center LP has disclosed compounds with dipyrrolopyridine structure acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of cancer, asthma, atopic dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and inflammatory bowel disease, among others.

Xuanzhu Pharma Co. Ltd. has described protein mono-ADP-ribosyltransferase TIPARP (PARP7; ARTD14) inhibitors reported to be useful for the treatment of cancer.

Redx Pharma plc has divulged GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Protego Biopharma Inc. and Scripps Research Institute have identified serine/threonine kinase/endoribonuclease IRE1 (ERN1) activators reported to be useful for the treatment of diabetes, myocardial infarction, nonalcoholic fatty liver disease (NAFLD), Parkinson's disease, retinal degeneration, atherosclerosis, Gaucher disease and Alzheimer's disease, among others.

Unnatural Products Inc. has synthesized cell-permeable cyclic peptides acting as E3 ubiquitin-protein ligase Mdm2 (Hdm2) and/or Mdm4 (Mdmx) inhibitors reported to be useful for the treatment of cancer.

Biocryst Pharmaceuticals Inc. has disclosed imidazole derivatives acting as activin receptor-like kinase 2 (ALK-2; ActR-IA) inhibitors reported to be useful for the treatment of diffuse intrinsic pontine glioma, spondyloarthritis and fibrodysplasia ossificans progressiva.

Erasca Inc. has described GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Medshine Discovery Inc. has divulged benzospiroheterocyclic derivatives acting as prostaglandin E receptor 4 (PTGER4; EP4 receptor) antagonists reported to be useful for the treatment of cancer.

Glycomimetics Inc. has identified glycosides acting as galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, inflammation, thrombosis, cardiovascular disorders, transplant rejection, neurodegeneration, fibrosis and liver diseases, among other disorders.